| Document |
Document Title |
|
WO/2024/059090A1 |
The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are prov...
|
|
WO/2024/057782A1 |
This agent for improving brain function comprises at least any of compounds represented by structural formulae (1)-(3).
|
|
WO/2024/059569A2 |
Provided herein are retroviral vector systems useful for producing universal pseudotyped retroviruses for cell and gene therapies. The vector systems include an envelope plasmid and a packaging plasmid, where at least one of these plasmi...
|
|
WO/2024/059631A1 |
Compositions and methods for selective targeting of Ml and/or M4 muscarinic receptors, compositions and methods for treating movement disorders, such as dystonia, with improved formulations of trihexyphenidyl, and in particular, composit...
|
|
WO/2024/056789A1 |
The disclosure provides a method of treating HIV infection in a human pediatric patient by the administration of cabotegravir or a pharmaceutically acceptable salt thereof, in combination with rilpivirine or a pharmaceutically acceptable...
|
|
WO/2024/059335A1 |
A method of treating and/or preventing retinal dysfunction in a subject in need thereof includes administering to the subject a therapeutically effective amount of a stress-resilience enhancing drug that promotes intrinsic mechanisms of ...
|
|
WO/2024/059494A1 |
Provided herein are methods of treating multiple myeloma, including multiple myeloma that is resistant to at least one therapeutic agent, comprising administering to a subject with multiple myeloma an inhibitor of Ubiquitin-Like with PHD...
|
|
WO/2024/055994A1 |
Disclosed are a crystal form of a naphthofuran-substituted glutarimide compound, and a preparation method therefor and the use thereof, and specifically disclosed are a crystal form of compound (1) and the preparation therefor.
|
|
WO/2024/056775A1 |
The present invention is directed to compounds of formula IIa. These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the inventi...
|
|
WO/2024/059808A1 |
Compounds of general Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive ...
|
|
WO/2024/059331A1 |
The present application discloses an erythritol analog of phenylbutyrate, and compositions including same. Also disclosed are methods of using the erythritol analog of phenylbutrate.
|
|
WO/2024/059659A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, Y1, Y2, X1, X2, X3, Q1, and Ra are as defined elsewhere herein. Also provid...
|
|
WO/2024/057195A1 |
The present invention relates to a pharmaceutical combination comprising 6α- ethyl -3α, 7 a- dihydroxy- 24 -nor- 5 β- cholan-23-ol or a pharmaceutically acceptable salt thereof and a statin and to a combination comprising 6α-ethyl-3Î...
|
|
WO/2024/058320A1 |
The present invention relates to a composition for preventing, alleviating, or treating an intestinal disease or malnutrition, and, according to the present invention, the composition can be used to alleviate a leaky gut phenomenon and i...
|
|
WO/2023/056139A9 |
The present disclosure provides genome editing compositions comprising a ribonucleoprotein (RNP) complex comprising: i) a class 2 CRISPR-Cas effector polypeptide, or a nucleic acid comprising a nucleotide sequence encoding the class 2 CR...
|
|
WO/2024/057039A1 |
The present invention relates to a method of treatment wherein a composition comprising a cannabinoid and an amphiphilic carbohydrate compound such as GCPQ is administered intranasally. The method of treatment is particularly suitable fo...
|
|
WO/2024/058252A1 |
A method according to the present invention is a method for predicting the therapeutic effect of pharmacotherapy in the treatment of a subject with metastatic prostate cancer, wherein the pharmacotherapy includes at least one selected fr...
|
|
WO/2024/059087A1 |
Disclosed are compounds represented by formulae (I) and (II): or a pharmaceutically acceptable salt thereof. Compounds of formula (I) and (II) are useful for treating coronavirus infection via inhibition of the protease Mpro.
|
|
WO/2024/056005A1 |
A compound represented by formula (I) CLM-L-PTM or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a use thereof, which are particularly suitable for preparing drugs for treating or preventin...
|
|
WO/2024/059853A2 |
The present disclosure provides novel compounds and their metal chelates, for diagnostic, therapeutic and/or theranostic use in the treatment of cancer, tumor and other oxygen activity related diseases. The novel compounds are analogues ...
|
|
WO/2024/059525A2 |
Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for anaplastic lymphoma kinase (ALK) an...
|
|
WO/2024/057352A1 |
Nausea and vomiting are unpleasant events induced by multiple triggers. Among them, drugs frequently prompt nnaauusseeaa and vomiting. Antitumor chemotherapeutics are among the most emetic drugs and often cause the so- called chemotherap...
|
|
WO/2024/058848A1 |
Topical pharmaceutical compositions comprising roflumilast and solvents that are capable of dissolving high amounts of roflumilast. The pharmaceutical compositions are capable of dissolving high amounts of roflumilast relative to other c...
|
|
WO/2024/055118A1 |
The present disclosure relates to a use of minor cannabinoids in the management or treatment of a seizure disorder in a patient. Minor cannabinoids include cannabichromene (CBC), cannabichromenic acid (CBCA), cannabigerol (CBG), cannabig...
|
|
WO/2024/059041A1 |
The present disclosure provides compounds and pharmaceutical compositions comprising the same. The compounds, pharmaceutical compositions thereof, and methods of using the same have a range of utilities as therapeutics, diagnostics, and ...
|
|
WO/2024/059107A1 |
Provided herein are compounds that promote targeted degradation of IKZF1, IKZF2, GSPT1, and/or CKla, proteins whose activities are implicated in the pathology of certain cancers (e.g., acute myeloid leukemia). Also provided are pharmaceu...
|
|
WO/2024/059608A1 |
Provided herein is a deuterated compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R15a, R15b, R16a, R16b, R17, R18, R19, R21a,...
|
|
WO/2024/057892A1 |
The present invention addresses the problem of providing a means for maintaining and enhancing the anti-tumor activity of TADC in a tumor microenvironment.　It was found that when a composition, "cPLs adjuvant," containing three types o...
|
|
WO/2024/055758A1 |
The present invention relates to the technical field of biological medicines. Disclosed are a cyclic dinucleotide metal compound, and a preparation method therefor and a use thereof. The structural formula of the compound is [M(cyclic di...
|
|
WO/2024/058077A1 |
Provided is a technology that can promote neuronal migration. This pharmaceutical composition for treating brain disease includes a neuraminidase inhibiting substance. This neuronal migration promoter includes a neuraminidase inhibiting ...
|
|
WO/2024/059336A1 |
Provided are methods and compositions for treating or preventing lymphedema by administering an inhibitor of the protease-activated receptor 2 (PAR2) pathway.
|
|
WO/2024/059705A1 |
The present invention relates to methods of treating depression in human females by administering a SIRT6 activator.
|
|
WO/2024/059085A1 |
The disclosure pertains to chemical entities such as a compound or a pharmaceutically acceptable salt that inhibit inflammatory responses by, for example, inhibiting the oligomerization of Apoptosis-associated speck-like protein containi...
|
|
WO/2024/057001A1 |
The present invention relates to compounds of Formula (I) that may act as agonists of retinoic acid receptor alpha (RAR-α) and/or retinoic acid receptor beta (RAR-β). The invention also relates to pharmaceutical compositions comprising...
|
|
WO/2024/059249A1 |
The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...
|
|
WO/2024/055932A1 |
An azacyclic compound, a composition thereof, and use thereof for preventing and/or treating a disease. Use of at least one of a compound represented by formula (I), a pharmaceutically acceptable salt of the compound represented by formu...
|
|
WO/2024/059010A1 |
The present application relates to compounds of Formula (A), as defined herein, and pharmaceutically acceptable salts thereof, as well as processes for preparing compounds of Formula (A), and pharmaceutically acceptable salts thereof. Th...
|
|
WO/2024/058255A1 |
The purpose of the present invention is to provide an agent for adjusting cytokine production by lipopolysaccharide derived from Escherichia coli, or an agent for adjusting TLR4 activation by lipopolysaccharide derived from Escherichia c...
|
|
WO/2024/058552A1 |
The present invention relates to a pharmaceutical composition for preventing or treating degenerative brain diseases, comprising cannabinoids as an active ingredient, and uses thereof. The present invention has confirmed that treatment w...
|
|
WO/2024/059696A1 |
This application discloses a combination therapy using a combination of a WEE1 inhibitor and a BRAF inhibitor, and optionally an EGFR inhibitor, for the treatment of a disease, such as colorectal cancer.
|
|
WO/2024/056995A1 |
The invention provides a combination of a PI3K/AKT/mTOR pathway inhibiting compound and a tanshinone or a derivative, an isomer or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/056062A1 |
The present invention relates to a steroid hormone-phospholipid composition and a preparation method therefor. The composition comprises a steroid hormone and phospholipid, and may further comprise cholesterol. The composition is prepare...
|
|
WO/2024/057332A1 |
The present invention relates to an improved process for the preparation of N- (3,5dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-py
razol-4-yl) quinoxalin-6-yl]ethane-1,2-diamine compound of formula-1 which is represented by the ...
|
|
WO/2024/056619A1 |
The present invention relates to new therapeutic uses of 1 H-Cyclopenta[b]benzofuran derivatives, specifically new uses for the treatment or prevention of a disease caused by virus infections or a disease associated with virus infections...
|
|
WO/2024/059161A1 |
The present disclosure provides novel methods for serotype-specific analysis of compositions comprising one or more polysaccharides. The polysaccharide content can exist as free polysaccharides, or polysaccharide in other forms, such as ...
|
|
WO/2024/059811A2 |
Compounds, polypeptides, compositions, and nucleic acid molecules are provided herein that can be used, for example, to edit the genome of a cell, such as a human cell.
|
|
WO/2024/056081A1 |
Provided are bifidobacterium breve B51 and B280, a product thereof, and use thereof. The bifidobacterium breve is B51 or B280. The B51 is collected in China General Microbiological Culture Collection Center of China Committee for Culture...
|
|
WO/2024/059491A1 |
The disclosure is directed to novel solid-state forms of Compound 9 and pharmaceutically acceptable salts of Compound 9, compositions comprising the same, and methods of using the same, including use in treating cancer, hypoxia related p...
|
|
WO/2024/059829A1 |
Provided are compositions and methods for protecting tissue of patients undergoing radiation therapy from off-target radiation damage. The compositions comprise a compound selected from the group consisting of: glipizide, etidronate, mer...
|
|
WO/2024/056101A1 |
The present invention relates to a linker for an antibody-drug conjugate and a use thereof. Specifically, a linker represented by formula I is provided. An antibody-drug conjugate prepared by means of the linker are more stable and more ...
|
